TerminatedPhase 4

Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision

Stopped: insufficient enrollment

South Korea19 participantsStarted 2013-01

Plain-language summary

The purpose of this study is to determine the effect of ranibizumab for the treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO) in patients with initial fair visual acuity.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Foveal center-involving macular edema secondary to BRVO diagnosed within 12 months before study enrollment
✓. ETDRS chart BCVA: 63 to 77 letters (20/32 to 20/50 Snellen equivalent)
✓. CFT \>= 300 um (mean of measurements obtained at screening and Day 0)
✓. Signed consent informed
✓. male or female, age ≥18 years old

Exclusion criteria

✕. Prior episode of RVO: Past history of RVO in the study eye diagnosed before 1 year of study enrollment.
✕. BCVA improvement \>10 letters between screening and Day 0
✕. History of other ocular diseases (e.g. diabetic retinopathy, age-related macular degeneration)
✕. Laser treatment within 3 months before baseline
✕. Intraocular corticosteroid use within 3 months before baseline
✕. Anti-vascular endothelial growth factor (VEGF) treatment in the study or fellow eye within 3 months before baseline
✕. Intraocular surgery other than cataract surgery, Cataract surgery within 6 months before baseline
✕. Stroke or myocardial infarction ≤3 months before baseline

What they're measuring

Time to achieve an improvement of 10 or more Early Treatment Diabetic Retinopathy Study (ETDRS) letters in best-corrected visual acuity

Timeframe: 1 year

Trial details

NCT IDNCT01795209

SponsorSeoul National University Bundang Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-12

View on ClinicalTrials.gov More Branch Retinal Vein Occlusion trials